InvestorsHub Logo
Followers 2775
Posts 77901
Boards Moderated 1
Alias Born 05/10/2007

Re: None

Tuesday, 09/06/2016 11:45:31 PM

Tuesday, September 06, 2016 11:45:31 PM

Post# of 234
OCUL: By End of this quarter is what they said. CEO at Morgan Stanley Conference next week. Seems to me he would want the FDA submission done by then.

Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 4:15 p.m. ET. The conference will be held at the Grand Hyatt Hotel in New York, NY.

Recently, the FDA issued a letter to Ocular Therapeutix noting that corrective actions detailed in its responses as a whole appear to address the ten inspectional observations raised in the Form FDA 483 with one exception which relates to the proposed process for identity testing of an incoming inert gas component used in the manufacturing process. In this letter, the FDA also requested that the Company provide evidence (e.g., a final report) when migration to automatic integration of analytical testing is complete, which is anticipated during the third quarter of 2016.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OCUL News